At ≥7 days after second dose, effectiveness of mRNA COVID-19 vaccine was 69 percent against infection, 86 percent against related death
Three Days of Remdesivir Cuts Risk for Severe COVID-19 in Outpatients
Three-day course of treatment results in reduced risk for hospitalization or death compared with placebo
Efficacy of Bamlanivimab for COVID-19 May Vary With Antibody Status
Further study needed to determine whether bamlanivimab could benefit patients who are negative for endogenous neutralizing antibodies
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Dec. 20 to 23, 2021. This …
Holidays Complicate Diabetes Management, Patients Report
Half of U.S. adults with diabetes say managing diabetes is more difficult during the holidays versus other times of the year
Percentage of Teens Reporting Drug Use Declined in 2021
Proportion of teens in grades 8, 10, and 12 reporting alcohol, marijuana use decreased significantly
FDA Gives OK to Merck Antiviral At-Home COVID-19 Pill
Molnupiravir cut the risk for hospitalization and death in high-risk patients by 30 percent